icon-folder.gif   Conference Reports for NATAP  
  The International Liver Congress™
EASL - European Association for the
Study of the Liver
2019 April 10-14
Vienna Austria
Back grey_arrow_rt.gif
A Combination of the ACC Inhibitor GS-0976 (firsocostat) and the Nonsteroidal FXR Agonist GS-9674 (cilofexor) Improves Hepatic Steatosis, Biochemistry, and Stiffness in Patients With Nonalcoholic Steatohepatitis
  Reported by Jules Levin
EASL 2019 April 10-14 Vienna







References: 1. Marra F, Svegliati-Baroni G. J Hepatol 2018;68:280-95; 2. Bates J, et al. AASLD 2017, abstr 425; 3. Bates J, et al. EASL 2018, abstr 3755; 4. Liles J, et al. EASL 2017, abstr PS-030; 5. Loomba R, et al. Gastroenterology 2018;155:1463-73; 6. Patel K, et al. AASLD 2018, abstr 736; 7. Lawitz EJ, et al. Clin Gastroenterol Hepatol 2018;16:1983-91; 8. Harrison S, et al. EASL 2018, abstr FRI-487; 9. Decaris ML, et al. PloS One 2015;10:e0123311; 10. Decaris ML, et al. Hepatology 2017;65:78-88; 11. Hellerstein MK, et al. Am J Physiol 1999:276:E1146-70. Acknowledgments: We extend our thanks to the patients and their families who participated in this study. This study was funded by Gilead Sciences, Inc.